Innate Pharma S.A. (OTCMKTS:IPHYF) Sees Large Growth in Short Interest

Innate Pharma S.A. (OTCMKTS:IPHYFGet Rating) saw a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 5,600 shares, a growth of 30.2% from the October 15th total of 4,300 shares. Based on an average daily trading volume, of 100 shares, the days-to-cover ratio is presently 56.0 days.

Innate Pharma Price Performance

Innate Pharma stock opened at $2.08 on Tuesday. The business has a 50 day moving average of $2.19 and a 200-day moving average of $2.55. Innate Pharma has a 1 year low of $1.93 and a 1 year high of $5.70.

Analyst Ratings Changes

Separately, Stifel Nicolaus started coverage on Innate Pharma in a research note on Friday, July 29th. They issued a “buy” rating for the company.

About Innate Pharma

(Get Rating)

Innate Pharma SA, a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers.

Recommended Stories

Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with's FREE daily email newsletter.